- Home
- CRL vs QGEN Comparison
CRL vs QGEN Comparison
Compare CRL & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRL | QGEN |
|---|---|---|
| Founded | 1947 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.8B | 10.2B |
| IPO Year | 1999 | 1998 |
Fundamental Metrics
Financial Performance| Metric | CRL | QGEN |
|---|---|---|
| Price | $224.30 | $41.08 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $198.27 | $45.76 |
| AVG Volume (30 Days) | 804.7K | ★ 2.8M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,857,601,000.00 | N/A |
| Revenue This Year | N/A | $8.18 |
| Revenue Next Year | $3.04 | $5.71 |
| P/E Ratio | ★ N/A | $24.01 |
| Revenue Growth | ★ 10.48 | N/A |
| 52 Week Low | $144.26 | $32.53 |
| 52 Week High | $238.85 | $57.82 |
Technical Indicators
Market Signals| Indicator | CRL | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.22 | 59.93 |
| Support Level | $218.39 | $38.24 |
| Resistance Level | $232.94 | $42.33 |
| Average True Range (ATR) | 8.15 | 1.25 |
| MACD | -2.14 | -0.08 |
| Stochastic Oscillator | 45.70 | 56.07 |
Price Performance
Historical ComparisonAbout CRL Charles River Laboratories International Inc.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).